Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Discovery and research, Finance and Investment

4Tissue Raises €2M to Advance Groundbreaking Breast Tissue Replacement Technology

Ghent, October 23, 2024 — 4Tissue, a pioneering biotech company revolutionizing regenerative medicine with its cutting-edge, bioresorbable hydrogel tissue mimic has successfully completed a €2M seed funding round including equity investment and non-dilutive grants. Led by three prominent female investors from the life science and business sectors, this funding will enable 4Tissue to accelerate the clinical development of its innovative platform. This investment underscores the transformative potential of 4Tissue in women’s health.

The rise and recalibration of sustainable agrifood investments: lessons for us all

There has been an unprecedented surge of investments in sustainable agriculture and food technologies in the last decade, but that trend now appears to have reversed into a free fall in funding. This pattern of promise-to-disillusionment perfectly matches the hype cycle previously demonstrated by breakthrough technologies in other sectors. Can we forge a path forward for sustainable agrifood start-ups?

Belgium’s ‘Positive for the Planet’ evolution through agritech

Our current food system is responsible for around a third of global greenhouse gas emissions, extensive deforestation, unsustainable water usage, and an unprecedented loss of biodiversity. Currently, the processes used to produce our food represent an obstacle to limiting average global temperature increases to the levels set out in the Paris Agreement. But are these damaging effects of our current food production landscape an unavoidable cost of feeding humanity or can smart investments in sustainable agritech be part of the solution?

Mutually beneficial success: the importance of the founder-VC partnership

The adage ‘teamwork makes the dream work’ rings especially true in the dynamic realm of biotech startups. Most successful biotech companies have a foundation built on a robust relationship between their founders and venture capital (VC) partners. This founder-VC partnership represents a symbiotic relationship between a venture capital firm and the founding team of a biotech startup. But what are the key factors for a successful partnership?

Luxembourg’s Vision for a Digital HealthTech Future

Luxembourg may be one of the smallest nations in the world, at just over 2,500 square kilometers and around 670,000 inhabitants, but it packs a punch in the global life sciences ecosystem. With world-class research institutes, startup accelerators, and the country’s growing digital prowess, Luxembourg is attracting global talent and putting digital healthtech solutions front and center. So, how did the Grand Duchy establish and grow its thriving research and startup landscape, and what is the vision for the future?

Anacura acquires OHMX.bio, adding multi-omics for drug discovery and diagnostics to its services

Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.

Axithra Strengthens its Board of Directors

The appointments of Dr. Alain Pluquet as Chairman of the Board and Mr. Michael Tillmann as Independent Director brings extensive industrial expertise to help develop Axithra’s long-term strategy

Bridging the gap between academia and the sports tech industry

For scientists or budding entrepreneurs with the next big idea in sports tech, the road from conceptualization to product can seem perilous, with many pitfalls along the way. To stand a chance at getting your research out of the lab and into the hands of athletes, it’s essential to start off on the right foot. Read on to see how the collaboration of scientists and sports tech development experts is helping this unique ecosystem in Belgium to flourish.

Flanders as a knowledge hub in the current Benelux life sciences ecosystem

At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.

V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

Fraud in scientific institutes: a crack in the fabric of science

The pursuit of scientific knowledge is at the heart of human progress – it leads to ground-breaking discoveries that have transformed our understanding of the world and our place within it. However, this noble pursuit is not without its blemishes. Scientific fraud – the deliberate misrepresentation of data or results to deceive the scientific community – poses a serious threat to the integrity of the scientific enterprise in both academia and industry. So, what can we do about it?

Fund+ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk in potential 1-billion-euro deal

Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in RNA-based therapies that have the potential to prevent, repair and reverse diseases of the heart. The company’s approach targets distinctive non-coding RNAs to address the root causes of cardiac dysfunctions and achieve lasting patient impact.

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Azalea Vision Secures Prestigious European Innovation Council (EIC) Transition Grant

Innovative Smart Contact Lens Developer Awarded €2.5M in Funding for Groundbreaking Ocular Health Technology

V-Bio Ventures portfolio company Protealis secures EUR 22 million in oversubscribed B round funding to propel sustainable plant protein seed solutions

Protealis, a leading innovator in seed solutions for sustainable plant proteins based in Ghent, Belgium, proudly announced today the successful completion of its B-Round funding, raising a substantial EUR 22 million.